Synta Pharmaceuticals Corp.  

(Public, NASDAQ:SNTA)   Watch this stock  
Find more results for SNTA
-0.28 (-9.43%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.64 - 3.02
52 week 1.85 - 4.97
Open 2.91
Vol / Avg. 3.41M/2.11M
Mkt cap 361.59M
P/E     -
Div/yield     -
EPS -0.89
Shares 134.42M
Beta 2.42
Inst. own 19%
May 6, 2015
Q1 2015 Synta Pharmaceuticals Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 24, 2015
Synta Pharmaceuticals Corp at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 12, 2015
Q4 2014 Synta Pharmaceuticals Corp. Earnings Release
Mar 12, 2015
Q4 2014 Synta Pharmaceuticals Corp Earnings Call - Webcast
Mar 9, 2015
Synta Pharmaceuticals Corp at ROTH Conference
Mar 4, 2015
Synta Pharmaceuticals Corp at Cowen Health Care Conference
Feb 10, 2015
Synta Pharmaceuticals Corp at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -72.78% -87.97%
Return on average equity -109.67% -150.86%
Employees 110 -
CDP Score - -


United States - Map
+1-781-2748200 (Phone)
+1-781-2748228 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. The Company has two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical stage of development. The Company�s lead drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in a broad development program including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia (AML). The Company is developing a platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates (HDCs). The Company�s inflammatory disease programs include CRACM Ion Channel Inhibitors and IL-12/23 Inhibitors.

Officers and directors

Keith R. Gollust Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Anne C. Whitaker President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Marc R. Schneebaum Chief Financial Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Chen Schor Chief Operating Officer, Executive Vice President
Age: 42
Bio & Compensation  - Reuters
Arthur J. McMahon Senior Vice President - People Operations
Age: 68
Bio & Compensation  - Reuters
Vojo Vukovic M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
Keith S. Ehrlich CPA Vice President of Finance - Administration
Age: 63
Bio & Compensation  - Reuters
Wendy E. Rieder Esq. Vice President - Intellectual Property and Legal Affairs, General Counsel
Age: 46
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Director
Age: 71
Bio & Compensation  - Reuters
Bruce S. Kovner Independent Director
Age: 69
Bio & Compensation  - Reuters